Nonmyeloablative Preparative Regimen Using Mylotarg for Patients With High Risk Acute Myeloid Leukemia (AML), Acute Lymphocytic Leukemia (ALL), Chronic Myeloid Leukemia (CML) and Myelodysplastic Syndrome (MDS)

• Status: Terminated
• Trial end date: 2004-11-01

Summary

Primary Objective:

To determine the safety and maximum tolerated dose of CMA-676 as part of an intensive but nonmyeloablative preparative regimen in older or medically infirm patients undergoing mini-allogeneic peripheral blood stem cell transplantation

Secondary Objectives:

1. To evaluate response rates, engraftment kinetics and degree of chimerism achievable with this strategy.

2. To evaluate disease-free and overall survival and relapse rates.

3. To evaluate the need and ability to give multiple cycles of Mylotarg plus FA and mobilized DLI in patients not achieving complete remission.

• Phase: Phase 2/Phase 3

Details

• Lead Sponsor: M.D. Anderson Cancer Center
• Collaborator: Wyeth is now a wholly owned subsidiary of Pfizer
• Treatments: Gemtuzumab